http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201906869-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_321b10c632ca3a14bdb685ff273c4f4c
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
filingDate 2018-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f37181e2e9bafdfcfc5a363d1b69148
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b8f001489f99d2aaa5378c49d8ee2bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b029ba7ed946450c4ade55075d24a2e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dc2bc00211c67dcac015d7b575fefd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbfbc3d35ecdd9a590eec5d99536c095
publicationDate 2019-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber TW-201906869-A
titleOfInvention Humanized antibody against GLOBO H and its use for treating cancer
abstract The present invention provides a humanized anti-Globo H antibody or its scFv or Fab fragment, which comprises a heavy chain variable domain having three complementary regions consisting of HCDR1, HCDR2 and HCDR3, and three comprising LCDR1, LCDR2 and LCDR3. The light chain variable domain of the complementary region, where the sequence of HCDR1 is GYISSDQILN (SEQ ID NO: 4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO: 5, where X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO: 6), where the sequence of LCDR1 is KSNQNLLX'SGNRRYZLV (SEQ ID NO: 7, where X 'is F, Y, or W, and Z is C, G, S, or T), and the sequence of LCDR2 is WASDRSF (SEQ ID NO: 8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO: 9).
priorityDate 2017-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555909
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419564492
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554054
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419548780
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483812
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45480568
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558042
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426285819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487901
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163606
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9060
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419564493
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6267
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419520675
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45480569
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73427344
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71077
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41206
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33032

Total number of triples: 48.